Biotech entity
Every one of those 1 sits in a single category, acquisition. Revlimid is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. Revlimid appears in 1 tracked Biotech story from August 2, 2026. The tracked stories average 2 original sources each.
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, acquisition. Revlimid is most often covered alongside AstraZeneca, which appears in 1 of these 1 story. Revlimid appears in 1 tracked Biotech story from August 2, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Revlimid. Shared-story counts are live from our verified record — not editorial picks.
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
Revlimid is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
